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Abstract Oral administration of sodium tungstate is an e¡ec-
tive treatment for diabetes in animal models. We examined the
e¡ects of 6 weeks of oral administration of tungstate on glucose
transporters (GLUT) in streptozotocin-induced diabetic rat dia-
phragm. Diabetes decreased GLUT4 expression while tungstate
treatment normalized not only GLUT4 protein but also GLUT4
mRNA in the diabetic rats. Furthermore, treatment increased
GLUT4 protein in plasma and internal membranes, suggesting a
stimulation of its translocation to the plasma membrane. Tung-
state had no e¡ect on healthy animals. There were no di¡er-
ences in the total amount of GLUT1 transporter in any group.
We conclude that the normoglycemic e¡ect of tungstate may be
partly due to a normalization of the levels and subcellular local-
ization of GLUT4, which should result in an increase in muscle
glucose uptake.
- 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
A key role of insulin is to facilitate the uptake of glucose
from blood into muscle and adipose tissues [1^4]. In muscle,
two glucose transporter isoforms are expressed, GLUT1 and
GLUT4. The latter is quantitatively more abundant in adult
rat muscle and is distributed among intracellular compart-
ments in the basal state, from where it is rapidly translocated
to the plasma membrane in response [3^5] to insulin [2,5,6] or
exercise [7,8]. GLUT1 is mainly located at the plasma mem-
brane [4] and is considered to be responsible for basal glucose
transport.
Insulin is the cornerstone of treatment for insulin-depen-
dent (type 1) and some forms of non-insulin-dependent
(type 2) diabetes mellitus [9]. Sodium tungstate may constitute
an alternative to insulin since both long- and short-term treat-
ments with this compound correct the hyperglycemia that
occurs in several rat models of diabetes mellitus types 1 and
2 [10^13]. Long-term tungstate treatment also prevents the
occurrence of various complications of diabetes in rats, such
as morphological changes in kidney and ocular lens, and also
reduces mortality but does not cause any undesirable side
e¡ects [12]. Tungstate normalizes hepatic carbohydrate metab-
olism in several animal models [10,11,13] while in neonatally
streptozotocin (STZ)-induced diabetic rats it restores L cell
function [11]. However, no studies have addressed the e¡ects
of this compound in skeletal muscle. Here we studied the
e¡ect of tungstate on the glucose transporters GLUT1 and
GLUT4 in diaphragm of healthy and STZ-induced diabetic
rats. Our results strongly support the notion that the normo-
glycemic e¡ects of tungstate are partially due to an increase in
muscle glucose uptake.
2. Materials and methods
2.1. Materials
Sodium tungstate, STZ and other biochemical reagents were pur-
chased from Sigma (St. Louis, MO, USA). All other reagents were of
analytical grade.
2.2. Animals and experimental design
Adult female Wistar rats, 140^150 g (Granada University breeding
colony), were housed at 22‡C in a light-controlled (12-h cycle) animal
facility and were allowed to eat and drink ad libitum. Experimental
diabetes was induced by a single STZ injection (60 mg/kg i.p. in 50
mM sodium citrate, pH 4.5) while control rats received citrate bu¡er
alone. Tail blood glucose levels were measured 10 days after STZ
injection and only animals with serum glucose levels greater than 20
mM were used. Treatment began 10 days after STZ injection and was
carried out for 6 weeks, during which £uid and food intakes and body
weight were measured weekly. Diabetic and healthy rats were divided
into two groups. The ¢rst (untreated) received drinking water whereas
a solution of 2 mg/ml sodium tungstate in water was given to the
second group (treated). Serum glycemia was determined by the glu-
cose oxidase^peroxidase method.
At the end of the experiment rats were killed by decapitation be-
tween 9.00 and 10.00 h; until this time the animals had free access to
food and water. After blood collection, diaphragm was removed, rap-
idly frozen in liquid nitrogen and kept at 380‡C until analysis. Ani-
mals were studied in compliance with our institutions’ guidelines for
animal research and the protocol was approved by the Animal Wel-
fare Committee.
2.3. Subcellular fractionation
Membrane fractions from diaphragm were prepared using a mod-
i¢cation of the di¡erential centrifugation method described by Klip et
al. [14]. 300 mg of tissue was minced and homogenized (1/10, w/v) by
Polytron 2U5 s, setting 4^5, in homogenization bu¡er (20 mM
NaHCO3, 0.25 M sucrose, 5 mM Na3N, 1 mM leupeptin, 1 mM
apoprotinin A, 1 mM pepstatin, pH 7.0) at 4‡C. The homogenate
was centrifuged at 1200Ug for 10 min and the pellet was resuspended,
homogenized and recentrifuged to remove debris. The combined
supernatants were centrifuged at 9000Ug for 10 min at 4‡C for mi-
tochondria and nuclei to sediment. The resulting supernatant was then
centrifuged at 190 000Ug for 60 min at 4‡C to obtain the total mem-
brane fraction. The membrane pellets were resuspended in homoge-
nization bu¡er and the total membrane protein content was measured
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by the Bradford method [15]. A pool of total membranes correspond-
ing to 6 mg of protein was layered on top of a discontinuous sucrose
density gradient (25, 30 and 35% sucrose, w/w) and centrifuged at
150 000Ug for 16 h at 4‡C. Plasma membranes were collected on
top of the 25% sucrose layer and low density microsomes on the
35% sucrose layer. Plasma membranes and low density microsomes
were washed by 10-fold dilution in 20 mM NaHCO3, 0.25 M sucrose,
5 mM Na3N and recovered by high speed centrifugation (190 000Ug
for 60 min at 4‡C). Membranes were resuspended in homogenization
bu¡er to a ¢nal concentration of 1^3 mg protein/ml and stored at
380‡C. 5P-Nucleotidase activity was measured as described [16] and
cytochrome c reductase activity was assayed following Mackler [17] as
marker enzymes for plasma membranes and low density microsomes,
respectively. Homogenates and membrane fractions were assayed for
Ca2þ-stimulated ATPase activity to exclude contamination of sarco-
plasmic reticulum [18].
2.4. GLUT1 and GLUT4 protein analyses
Electrophoresis in 12% sodium dodecyl sulfate (SDS)^polyacryl-
amide gels of diaphragm membrane fractions (10 Wg for total, 3 Wg
for plasma membranes and 6 Wg protein for low density microsomes)
was performed and the resolved proteins were transferred to nitro-
cellulose ¢lter membranes (Millipore, Bedford, MA, USA). Samples
were also analyzed individually by blotting 10 Wg protein of each
membrane fraction sample onto nitrocellulose membranes using a
slot blot apparatus (Bio-Rad, Hercules, CA, USA). After transfer,
the membranes were blocked in 5% non-fat milk and incubated
with a 1:600 dilution of a polyclonal anti-GLUT1 antibody (Santa
Cruz Biotechnologies, Santa Cruz, CA, USA) or a 1:500 dilution of a
polyclonal anti-GLUT4 antibody (East Acres Biologicals, South-
bridge, MA, USA). The antigen^antibody complexes were detected
with horseradish peroxidase-conjugated secondary antibodies using
an enhanced chemiluminescence detection system (Amersham, Amer-
sham, UK). In each case, the Western Blot autoradiograms revealed a
single band of 45 kDa, compatible with the molecular weight of the
transporters. Quanti¢cation was performed by densitometry after
scanning the autoradiographs with the NIH Image Software [19].
2.5. RNA isolation and Northern blot analysis
Total RNA was isolated from diaphragm of healthy and diabetic
rats using a guanidinium thiocyanate method [20]. For Northern blot
analysis, 10 Wg of RNA was electrophoresed on a 1.0% agarose^5%
formaldehyde gel and transferred using a 10Usodium chloride/sodium
citrate bu¡er (SSC) solution to BrightStar-Plus positively charged
nylon membranes (Ambion, Austin, TX, USA). For slot blot analysis,
10 Wg of the individual RNA samples was spotted onto BrightStar-
Plus membranes. After ultraviolet crosslinking, the ¢lters were initially
prehybridized for 3 h and then hybridized in Northern Max Prehyb/
Hyb bu¡er (Ambion) for 18 h at 42‡C with a random primer labeled
cDNA probe for GLUT4 [21]. Finally, the blots were washed once in
2USSC and 0.1% SDS at room temperature and three times in de-
creasing concentrations (1U to 0.1U) of SSC and 0.1% SDS at 65‡C.
Blots were exposed to Kodak Biomax ¢lm and intensifying screen at
380‡C. The relative amount of mRNA in each sample was quanti¢ed
by densitometric analysis using the NIH Image Software [19] and the
data were normalized to L-actin mRNA [22].
2.6. Statistical methods
Results are expressed as meansTS.E.M. for the indicated number
of rats. The data from two independent groups were compared by the
Mann^Whitney U-test. A P value 6 0.05 was considered signi¢cant.
3. Results
3.1. E¡ects of tungstate treatment on blood parameters and
physical status
After 6 weeks of treatment, glycemia in treated diabetic rats
decreased signi¢cantly (from 38.3T 5.0 to 9.0T 0.5 mM),
although it remained slightly higher than in their healthy
counterparts. Remarkably, tungstate did not modify glucose
concentration in healthy rats (6.8 T 0.3 vs. 6.9 T 0.4 mM) (Ta-
ble 1). Untreated diabetic rats increased food and liquid con-
sumption. Tungstate treatment reduced both parameters. As
previously reported [12], after 6 weeks of treatment, healthy
and diabetic rats showed a decrease in body weight.
3.2. E¡ects of tungstate treatment on glucose transporters in
diaphragm
The amounts of GLUT4 and GLUT1 in total membrane
fractions were measured by Western blotting. These assays
showed a single band of 45 kDa when probed for each trans-
porter (data not shown). Untreated diabetic rats presented a
40% decrease in the protein content of this transporter when
compared to healthy animals (Table 2). Tungstate treatment
of diabetic rats completely restored the levels of GLUT4 while
it did not alter the levels of this transporter in healthy rats.
The amount of GLUT1 protein was not signi¢cantly a¡ected
by diabetes or tungstate administration (Table 2).
Next, GLUT4 mRNA levels were measured in diaphragm
by Northern blot. The assay (Fig. 1) showed a single band of
2.8 kb corresponding to that described for the glucose trans-
porter [21]. Intensity data were normalized to the values of
L-actin. A 60% reduction in mRNA levels was observed in the
untreated diabetic rats when compared with their healthy
counterparts. Treated diabetic rats showed a signi¢cantly
higher GLUT4 mRNA content than untreated diabetic ani-
mals, although it was still slightly lower than in healthy rat
samples. However, in healthy rats, treatment did not modify
the amount of GLUT4 mRNA.
Table 1
Serum glucose, body weight, £uid, food and tungstate intake in treated or untreated healthy and diabetic rats
Serum glucose
(mM)
Body weight
(g)
Food intake
(g/kg/day)
Fluid intake
(ml/kg/day)
Tungstate intake
(mg/kg/day)
Healthy rats
Untreated (18) 6.8T 0.3 222.3T 4.6 77.4T 3.7 133.6T 7.0
Treated (16) 6.9T 0.4 203.2T 5.9e 89.8T 2.2e 123.0T 3.0 246.1T 5.9
Diabetic rats
Untreated (15) 38.3T 5.0a 176.0T 4.8a 138.9T 3.1a 660.5T 16.9a
Treated (12) 9.0T 0.5a;b;d 151.3T 9.0a;f 74.0 T 2.2b;c 185.9T 12.4a;b;c 371.8T 24.8c
Serum glucose values and body weight are those at the end of the experiment. Food, £uid and tungstate intake are the average consumption of
the last week of treatment. Results are expressed as the meansTS.E.M. for the number of rats indicated in parentheses.
aP6 0.001 compared with untreated healthy rats.
bP6 0.001 compared with untreated diabetic rats.
cP6 0.001 compared with treated healthy rats.
dP6 0.01 compared with treated healthy rats.
eP6 0.05 compared with untreated healthy rats.
fP6 0.05 compared with untreated diabetic rats.
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3.3. Characteristics of subcellular membrane fractions of rat
diaphragm muscle
To assay the distribution of glucose transporters in the
plasma membranes and low density microsomes of rat dia-
phragm, a subcellular fractionation was carried out. The ac-
tivity of 5P-nucleotidase in the isolated plasma membranes
from all rat groups was higher compared with that of the
low density microsomes. By contrast, low density microsomes
showed a higher cytochrome c reductase activity than plasma
membranes. In addition, the four groups showed similar
marker activities in each of the isolated subcellular fractions,
indicating a similar degree of purity regardless of the condi-
tions of each group (Table 3). Ca2þ-ATPase, a sarcoplasmic
reticulum marker enzyme, was not detectable or barely detect-
able in the membrane preparations (results not shown), dem-
onstrating absence of signi¢cant sarcoplasmic reticulum con-
tamination.
3.4. E¡ects of tungstate treatment on GLUT4 distribution
To determine whether tungstate modi¢es the distribution of
GLUT4, we quanti¢ed it in isolated plasma membranes and
low density microsomes. A 60^70% reduction of the protein of
this transporter was observed in untreated diabetic rats when
compared with healthy counterparts in both fractions. Tung-
state treatment induced a signi¢cant increase in GLUT4 in
diabetic rats, both in plasma membrane and in low density
microsomes, reaching levels similar to those of healthy ani-
Table 2
E¡ects of sodium tungstate on GLUT4 and GLUT1 expression in rat diaphragm
Healthy rats Diabetic rats
Untreated Treated Untreated Treated
GLUT4 protein 100.0T 4.2 90.4T 2.3 60.9T 2.4a 98.4T 2.7b
GLUT1 protein 100.0T 8.7 105.2T 5.8 91.5T 6.5 91.5T 5.9
E¡ect of sodium tungstate on total membrane fraction GLUT4 and GLUT1 protein in healthy and diabetic rats. Quanti¢cation was performed
by densitometry after scanning the autoradiographs corresponding to the Western blot determinations, as described in Section 2. Signal den-
sities from untreated healthy animals were assigned a value of 100% for each transporter. Results are expressed as the meansTS.E.M. for eight
rats per condition.
aP6 0.001 compared with untreated healthy rats.
bP6 0.001 compared with untreated diabetic rats.
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Fig. 1. E¡ects of sodium tungstate on GLUT4 mRNA levels in rat
diaphragm. Diaphragm total RNA was prepared and 10 Wg RNA
samples were analyzed by Northern blot as described in Section 2.
A: Representative Northern blots showing GLUT4 and L-actin
mRNAs in untreated healthy (UH), treated healthy (TH), untreated
diabetic (UD) and treated diabetic (TD) rats. B: Densitometric
quanti¢cation of GLUT4 mRNA abundance in rat diaphragm.
GLUT4 signal density from untreated healthy animals was assigned
a value of 100%. Results were normalized to the L-actin mRNA sig-
nal. Values are the meansTS.E.M. (n=7). aP6 0.001 compared
with untreated healthy rats, bP6 0.01 compared with untreated
healthy rats, cP6 0.001 compared with untreated diabetic rats.
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Fig. 2. E¡ects of sodium tungstate on GLUT4 expression in plasma
membranes and low density microsomes from rat diaphragm. Dia-
phragm subcellular membranes were obtained and protein samples
(3 Wg of plasma membranes and 6 Wg of low density microsomes)
were analyzed by SDS^PAGE and Western blotting as described in
Section 2. A: Representative Western blots showing GLUT4 protein
in plasma membrane (PM) and low density microsomes (LDM)
from untreated healthy (UH), treated healthy (TH), untreated dia-
betic (UD) and treated diabetic (TD) rats. B: Densitometric quanti-
¢cation of plasma (F) and internal membrane (E) GLUT4 protein
abundance in rat diaphragm. Signal densities from untreated healthy
animals were assigned a value of 100%. Values are the meansT
S.E.M. (n=5). aP6 0.001 compared with untreated healthy rats,
bP6 0.001 compared with untreated diabetic rats, cP6 0.01 com-
pared with untreated diabetic rats.
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mals. Tungstate had no e¡ect on GLUT4 protein in either of
these fractions of healthy rats (Fig. 2).
4. Discussion
Tungstate is an e¡ective agent for normalizing glycemia in
STZ-diabetic rats [10,12]. Here we studied the e¡ect of this
compound on the glucose transporters GLUT1 and GLUT4
in rat diaphragm. We show that tungstate produces a normal-
ization of the levels of GLUT4, indicating that an increase in
glucose transport in muscle is also involved in the mechanism
by which tungstate exerts its antidiabetic action. GLUT1,
which was not altered by diabetes, was una¡ected by tung-
state administration.
GLUT4 protein and GLUT4 mRNA content decreased in
untreated diabetic rats. GLUT4 expression is down-regulated
when there is a relative insulin de¢ciency, such as in STZ-
induced diabetes and chronic fasting [24]. Our results demon-
strate that tungstate treatment to diabetic rats partially re-
stores GLUT4 mRNA levels, which results in the complete
normalization of the protein levels. Similar results have been
shown in adipocytes isolated from STZ-induced diabetic rats
treated with vanadate [23,25]. The di¡erences in the degree of
restoration of protein and mRNA levels could be explained by
the fact that this gene is regulated extensively at the post-
transcriptional level. In several situations, including dietetic
treatment of diabetes [26], the GLUT4 protein and/or
mRNA can be stabilized, thereby increasing the total amount
of the transporter. Tungstate treatment may induce a similar
process.
The e¡ects of tungstate on GLUT4 distribution in skeletal
muscle of STZ-diabetic rats clearly di¡er from those of other
antidiabetic agents. Our results show that oral administration
of sodium tungstate increases the amount of this transporter
in both low density microsomes and plasma membranes. Va-
nadium derivatives increase the GLUT4 content in low den-
sity microsomes but not in plasma membranes of adipose
tissue [27,28] or skeletal muscle [29]. Troglitazone, a therapeu-
tic agent used to treat type 2 diabetic patients with insulin
resistance, increases the GLUT4 content of plasma membrane
by inducing its translocation from intracellular pools [30],
without causing a net increase in the total amount of the
transporter.
Insulin increases glucose uptake in its target tissues, muscle
and fat, by inducing the translocation of GLUT4 from an
intracellular pool to the plasma membrane [3^5]. Our results
show that tungstate also triggers the translocation of GLUT4
in treated diabetic rats since in plasma membranes this com-
pound induced a signi¢cant increase in GLUT4 content,
which reached levels that were similar to those in untreated
healthy rats. Tungstate had no e¡ect on the protein expression
of this transporter in internal or plasma membranes of healthy
rats.
In conclusion, tungstate, like insulin, exerts pleiotropic ef-
fects that also involve the muscle. The increase in GLUT4,
which should result in augmented muscle glucose uptake, may
also contribute to the normoglycemic e¡ect of this compound.
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